메뉴 건너뛰기




Volumn 1, Issue 3, 2001, Pages 145-146

Fluoroquinolones as pneumococcal therapy: Closing the barn door before the horse escapes

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; OFLOXACIN;

EID: 0035496429     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00090-1     Document Type: Letter
Times cited : (21)

References (19)
  • 1
    • 85120195558 scopus 로고    scopus 로고
    • Fishman NO, Suh B, Weigel LM, et al. Three levofloxacin treatment failures of pneumococcal respiratory tract infections. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 1999; San Francisco. Abstract 825.
  • 2
    • 85120219889 scopus 로고    scopus 로고
    • Davidson RJ, DeAzavedo J, Bast D, et al. Levofloxacin treatment failure of pneumococcal pneumonia and development of resistance during therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2000; Toronto. Abstract 2103.
  • 3
    • 85120200803 scopus 로고    scopus 로고
    • Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Inf Dis (in press).
  • 4
    • 0024996317 scopus 로고
    • Superinfection with Streptococcus penumoniae during therapy with ciprofloxacin
    • JJ Gordon CA Kaufmann Superinfection with Streptococcus penumoniae during therapy with ciprofloxacin Am J Med 89 1990 383 384
    • (1990) Am J Med , vol.89 , pp. 383-384
    • Gordon, JJ1    Kaufmann, CA2
  • 5
    • 85120188064 scopus 로고
    • Reflection & Reaction Infectious complications with respiratory pathogens despite ciprofloxacin therapy
    • BL Lee RC Kimbrough SR Jones Reflection & Reaction Infectious complications with respiratory pathogens despite ciprofloxacin therapy N Eng J Med 25 1991 520 521
    • (1991) N Eng J Med , vol.25 , pp. 520-521
    • Lee, BL1    Kimbrough, RC2    Jones, SR3
  • 6
    • 0028206249 scopus 로고
    • Fluoroquinolones in chronic obstructive pulmonary disease
    • A Colville M Knowles D Large Fluoroquinolones in chronic obstructive pulmonary disease BMJ 308 1994 1437
    • (1994) BMJ , vol.308 , pp. 1437
    • Colville, A1    Knowles, M2    Large, D3
  • 7
    • 0029125511 scopus 로고
    • Lower respiratory tract infection therapy–the role of ciprofloxacin
    • AP Ball GS Tillotson Lower respiratory tract infection therapy–the role of ciprofloxacin Int J Med Res 23 1995 315 327
    • (1995) Int J Med Res , vol.23 , pp. 315-327
    • Ball, AP1    Tillotson, GS2
  • 8
    • 0031031527 scopus 로고    scopus 로고
    • Trends in bacterial resistance to fluoroquinolones
    • J Acar F Goldstein Trends in bacterial resistance to fluoroquinolones Clin Infect Dis 24 1997 S67 S73
    • (1997) Clin Infect Dis , vol.24 , pp. S67-S73
    • Acar, J1    Goldstein, F2
  • 9
    • 0029794181 scopus 로고    scopus 로고
    • Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
    • X-S Pan J Ambler S Mehtar LM Fisher Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae Antimicrob Agents Chemother 40 1996 2321 2326
    • (1996) Antimicrob Agents Chemother , vol.40 , pp. 2321-2326
    • Pan, X-S1    Ambler, J2    Mehtar, S3    Fisher, LM4
  • 10
    • 0035882293 scopus 로고    scopus 로고
    • A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae
    • K Weiss C Restieri R Gauthier A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae Clin Infect Dis 33 2001 517 522
    • (2001) Clin Infect Dis , vol.33 , pp. 517-522
    • Weiss, K1    Restieri, C2    Gauthier, R3
  • 11
    • 0032803964 scopus 로고    scopus 로고
    • Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus
    • Y Dong X Zhao J Domagala K Drlica Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus Antimicrob Agents Chemother 43 1999 1756 1758
    • (1999) Antimicrob Agents Chemother , vol.43 , pp. 1756-1758
    • Dong, Y1    Zhao, X2    Domagala, J3    Drlica, K4
  • 12
    • 0028227016 scopus 로고
    • Comparative pharmacokinetics and safety of ciprofloxacin 400 mg iv thrice daily versus 750 mg PO twice daily
    • A Shah J Lettieri L Kaiser R Echols A Heller Comparative pharmacokinetics and safety of ciprofloxacin 400 mg iv thrice daily versus 750 mg PO twice daily J Antimicrob Chemother 33 1994 795 801
    • (1994) J Antimicrob Chemother , vol.33 , pp. 795-801
    • Shah, A1    Lettieri, J2    Kaiser, L3    Echols, R4    Heller, A5
  • 13
    • 0030864108 scopus 로고    scopus 로고
    • Pharmacokinetic profile of levofloxacin following once-daily 500 mg oral or intravenous doses
    • S-H Chien McRogge L Gisclon Pharmacokinetic profile of levofloxacin following once-daily 500 mg oral or intravenous doses Antimicrob Agents Chemother 41 1997 2256 2260
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 2256-2260
    • Chien, S-H1    McRogge2    Gisclon, L3
  • 14
    • 0032929072 scopus 로고    scopus 로고
    • In vitro activity of quinolones
    • A Dalhoff In vitro activity of quinolones Exp Opin Invest Drugs 8 1999 123 137
    • (1999) Exp Opin Invest Drugs , vol.8 , pp. 123-137
    • Dalhoff, A1
  • 15
    • 0035139520 scopus 로고    scopus 로고
    • Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae
    • J Blondeau X Zhao G Hansen K Drlica Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 433 438
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 433-438
    • Blondeau, J1    Zhao, X2    Hansen, G3    Drlica, K4
  • 16
    • 0025874801 scopus 로고
    • Antistaphylococcal activity of the fluoroquinolones CI-960, PD131628, sparfloxacin, ofloxacin, and ciprofloxacin
    • AL Barry PC Fuchs Antistaphylococcal activity of the fluoroquinolones CI-960, PD131628, sparfloxacin, ofloxacin, and ciprofloxacin Eur J Clin Microbiol Infect Dis 10 1991 168 171
    • (1991) Eur J Clin Microbiol Infect Dis , vol.10 , pp. 168-171
    • Barry, AL1    Fuchs, PC2
  • 17
    • 0025142610 scopus 로고
    • Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin
    • A Chaudhry C Knapp J Sierra-Madero J Washington Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin Antimicrob Agents Chemother 34 1990 1843 1845
    • (1990) Antimicrob Agents Chemother , vol.34 , pp. 1843-1845
    • Chaudhry, A1    Knapp, C2    Sierra-Madero, J3    Washington, J4
  • 18
    • 0033485614 scopus 로고    scopus 로고
    • Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS
    • F-J Schmitz A Fluit S Brisse J Verhoef K Koher D Milatovic Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 26 1999 281 287
    • (1999) Immunol Med Microbiol , vol.26 , pp. 281-287
    • Schmitz, F-J1    Fluit, A2    Brisse, S3    Verhoef, J4    Koher, K5    Milatovic, D6
  • 19
    • 0035077214 scopus 로고    scopus 로고
    • Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis
    • D Sahm J Karlowsky L Kelly Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis Antimicrob Agents Chemother 45 2001 1037 1042
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 1037-1042
    • Sahm, D1    Karlowsky, J2    Kelly, L3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.